Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed, operable stage IIIB non-small cell lung cancer~  * T4 N0-3 M0 or T1-4 N3 M0 by bronchoscopy and mediastinoscopy (required for assessment of N3 disease) or CT scan or MRI of the thorax~ * Squamous cell~ * Adenosquamous cell~ * Large cell~ * Poorly differentiated~* No prior or concurrent metastatic disease by CT scan or MRI of the brain, bone scan, and abdominal ultrasound or CT scan~* No malignant pleural or pericardial effusion~* No invasion of the aorta, esophagus, myocardium, or supraclavicular nodes~PATIENT CHARACTERISTICS:~Age:~* 18 to 75~Performance status:~* WHO 0-1~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 4,000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin normal~* AST and/or ALT no greater than 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 2.5 times ULN~Renal:~* Creatinine clearance at least 60 mL/min~Cardiovascular:~* No unstable cardiac disease requiring treatment~* No congestive heart failure~* No angina pectoris (even if medically controlled)~* No significant arrhythmia~* No myocardial infarction within the past 3 months~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No definite contraindications for the use of corticosteroids as premedication~* No preexisting grade 2 or greater peripheral neuropathy~* No active uncontrolled infection~* No uncontrolled diabetes mellitus~* No other prior or concurrent malignancy except non-melanomatous skin cancer or adequately treated carcinoma in situ of the cervix~* No prior significant neurologic or psychiatric disorders including psychotic disorders, dementia, or seizures that would preclude informed consent~* No other serious underlying medical condition that would preclude study participation~* No socioeconomic or geographical circumstances that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Not specified~Endocrine therapy:~* No concurrent corticosteroids except as prophylactic pretreatment medication, treatment for acute hypersensitivity reactions, or chronic treatment (initiated more than 6 months ago) at low-dose (no more than 20 mg methylprednisolone or equivalent)~Radiotherapy:~* No prior radiotherapy to the chest~Surgery:~* See Disease Characteristics~Other:~* At least 30 days since prior treatment in a clinical trial~* No prior cytostatic therapy~* No other concurrent experimental drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).